Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경효 | * |
dc.date.accessioned | 2019-07-29T16:30:06Z | - |
dc.date.available | 2019-07-29T16:30:06Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 2164-5515 | * |
dc.identifier.issn | 2164-554X | * |
dc.identifier.other | OAK-25148 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/250197 | - |
dc.description.abstract | In many countries, a second dose of a combined measles, mumps, and rubella (MMR) vaccine is recommended at 4-6 years of age - similarly to the booster of diphtheria, tetanus, acellular pertussis, and inactivated polio vaccine (DTaP-IPV) and the second dose of varicella vaccine (VV). Vaccine co-administration is generally encouraged if no interferences exist among the vaccines. This phase IIIa, randomized, controlled trial (NCT01621802) evaluated the immunogenicity and safety of MMR-RIT (Priorix, GSK) when given as a second dose with or without co-administration of DTaP-IPV and VV, using MMR II (M-M-R II, Merck & Co Inc.) as comparator. Antibody geometric mean concentrations or titers (GMCs/GMTs) and response rates to the components of all the administered vaccines were assessed. Solicited, unsolicited, and serious adverse events were recorded. Four thousand eleven children aged 4-6 years were enrolled. MMR-RIT elicited immune responses that were not inferior to those of MMR II in terms of GMCs and seroresponse rates when administered alone or when co-administered with DTaP-IPV and VV. The immune responses to the co-administered vaccines in MMR-RIT recipients were non-inferior to those in MMR II recipients. MMR-RIT and MMR II demonstrated similar reactogenicity profiles; the most frequent solicited adverse events across vaccine groups and sub-cohorts were local pain and fever. In conclusion, the immunogenicity and safety profiles of MMR-RIT administered with or without DTaP-IPV and VV were similar to those of MMR II. | * |
dc.language | English | * |
dc.publisher | TAYLOR & | * |
dc.publisher | FRANCIS INC | * |
dc.subject | Measles-mumps-rubella vaccine | * |
dc.subject | DTaP-IPV | * |
dc.subject | varicella vaccine | * |
dc.subject | immunogenicity | * |
dc.subject | safety | * |
dc.subject | co-administration | * |
dc.title | A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration | * |
dc.type | Article | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 15 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 786 | * |
dc.relation.lastpage | 799 | * |
dc.relation.journaltitle | HUMAN VACCINES & IMMUNOTHERAPEUTICS | * |
dc.identifier.doi | 10.1080/21645515.2018.1554971 | * |
dc.identifier.wosid | WOS:000467847400006 | * |
dc.author.google | Chiu Nan-Chang | * |
dc.author.google | Clifford, Robert | * |
dc.author.google | Huang Li-Min | * |
dc.author.google | Huang Yhu-Chering | * |
dc.author.google | Jo, Dae Sun | * |
dc.author.google | Kim, Chun Soo | * |
dc.author.google | Kim, Hwang Min | * |
dc.author.google | Kim, Kwang-Nam | * |
dc.author.google | Kim, Kyung-Hyo | * |
dc.author.google | Kim, Yun-Kyung | * |
dc.author.google | Klein, Nicola P. | * |
dc.author.google | Ma, Sang-Hyuk | * |
dc.author.google | Peltier, Christopher | * |
dc.author.google | Senders, Shelly | * |
dc.author.google | Shepard, Julie | * |
dc.author.google | Wu, Tsung Zu | * |
dc.author.google | Yeh, Shu Jen | * |
dc.author.google | Zissman, Edward | * |
dc.author.google | Gillard, Paul | * |
dc.author.google | Povey, Michael | * |
dc.author.google | Abu-Elyazeed, Remon | * |
dc.author.google | Henry, Ouzama|MMR-158 Study Grp | * |
dc.contributor.scopusid | 김경효(35448653000) | * |
dc.date.modifydate | 20240301081003 | * |